Korean Journal of Schizophrenia Research (대한조현병학회지)

Korean Society for Schizophrenia Research (대한조현병학회)
권호 표지
DOI QR코드

DOI QR Code

Association Study between Serotonin 1A Receptor Gene rs6295 Polymorphism and Tardive Dyskinesia in Patients with Schizophrenia

조현병 환자에서의 지연성 운동이상 발생과 세로토닌 1A 수용체유전자 rs6295 다형성과의 연관성

  • Lee, Youn-Jung (Department of Psychiatry, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital) ;
  • Namgoong, Yoon (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Cho, Areum (Department of Psychiatry, Korea University College of Medicine) ;
  • Lee, Heon-Jeong (Department of Psychiatry, Korea University College of Medicine)
  • 이윤정 (경상대학교병원 정신건강의학과학교실) ;
  • 남궁윤 (고려대학교구로병원 내과) ;
  • 조아름 (고려대학교 의과대학 정신건강의학교실) ;
  • 이헌정 (고려대학교 의과대학 정신건강의학교실)
  • Received : 2020.06.26
  • Accepted : 2020.09.24
  • Published : 2020.10.30
⟨ Previous Next ⟩

Abstract

Objectives: Tardive dyskinesia (TD) is a movement disorder that is characterized by hyperkinetic movements. Previous studies have suggested that the serotonergic systems are correlated with TD vulnerability. In this study, the association between a single-nucleotide polymorphism (SNP) of the serotonin 1A receptor gene (HTR1A) rs6295 and TD was investigated. Methods: We investigated whether HTR1A rs6295 SNP is associated with antipsychotic-induced TD in 280 Korean patients with schizophrenia. Patients with schizophrenia having TD (n=105) and those without TD (n=175) were matched for their antipsychotic exposures and other relevant variables. The HTR1A rs6295 SNP was analyzed using polymerase chain reaction (PCR)-based methods. Results: There was no significant difference in the distribution of genotypic (χ2=2.70, p=0.26) and allelic (χ2=1.87, p=0.17) frequencies between the patient groups with TD and without TD. There was no significant difference in total abnormal involuntary movement scale score (F=0.39, p=0.68) among the genotype group either. Conclusion: Although there were no differences in genotypic and allelic frequency between patient groups with and without TD, further studies on association of TD with other SNPs of HTRA1 are needed to understand the pathophysiological mechanism of TD.

Keywords

References

  1. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010;71:463-474. https://doi.org/10.4088/JCP.07m03890yel
  2. Stegmayer K, Walther S, van Harten P. Tardive dyskinesia associated with atypical antipsychotics: prevalence, mechanisms and management strategies. CNS Drugs 2018;32:135-147. https://doi.org/10.1007/s40263-018-0494-8
  3. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991;4:109-120. https://doi.org/10.1016/0920-9964(91)90029-Q
  4. Frei K. Tardive dyskinesia: who gets it and why. Parkinsonism Relat Disord 2019;59:151-154. https://doi.org/10.1016/j.parkreldis.2018.11.017
  5. Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T, et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001;104:375-379. https://doi.org/10.1034/j.1600-0447.2001.00401.x
  6. Weinhold P, Wegner JT, Kane JM. Familial occurrence of tardive dyskinesia. J Clin Psychiatry 1981;42:165-166.
  7. Baldessarini RJ. The pathophysiologic basis of tardive dyskinesia. Psychopharmacol Bull 1978;14:79-81.
  8. Andreassen OA, Jorgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 2000;61:525-541. https://doi.org/10.1016/S0301-0082(99)00064-7
  9. Haleem DJ, Khan NH. Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:645-651. https://doi.org/10.1016/S0278-5846(03)00074-5
  10. Naidu PS, Kulkarni SK. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur J Pharmacol 2001;428:81-86. https://doi.org/10.1016/S0014-2999(01)01284-5
  11. Mason SL, Reynolds GP. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur J Pharmacol 1992;221:397-398. https://doi.org/10.1016/0014-2999(92)90731-I
  12. Newman-Tancredi A, Chaput C, Verriele L, Millan MJ. Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors. Neuropharmacology 1996;35:119-121. https://doi.org/10.1016/0028-3908(95)00170-0
  13. Prinssen EP, Kleven MS, Koek W. Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology (Berl) 1999;144:20-29. https://doi.org/10.1007/s002130050972
  14. Le Francois B, Czesak M, Steubl D, Albert PR. Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology 2008;55:977-985. https://doi.org/10.1016/j.neuropharm.2008.06.046
  15. Varnas K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 2004;22:246-260. https://doi.org/10.1002/hbm.20035
  16. Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res 1996;708:209-214. https://doi.org/10.1016/0006-8993(95)01361-X
  17. Wang L, Fang C, Zhang A, Du J, Yu L, Ma J, et al. The--1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol 2008;22:904-909. https://doi.org/10.1177/0269881107081522
  18. Kishi T, Okochi T, Tsunoka T, Okumura T, Kitajima T, Kawashima K, et al. Serotonin 1A receptor gene, schizophrenia and bipolar disorder: an association study and meta-analysis. Psychiatry Res 2011;185:20-26. https://doi.org/10.1016/j.psychres.2010.06.003
  19. Mossner R, Schuhmacher A, Kuhn KU, Cvetanovska G, Rujescu D, Zill P, et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics 2009;19:91-94. https://doi.org/10.1097/FPC.0b013e328311a917
  20. Kishi T, Yoshimura R, Fukuo Y, Okochi T, Matsunaga S, Umene-Nakano W, et al. The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2013;263:105-118. https://doi.org/10.1007/s00406-012-0337-4
  21. Huang YY, Battistuzzi C, Oquendo MA, Harkavy-Friedman J, Greenhill L, Zalsman G, et al. Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. Int J Neuropsychopharmacol 2004;7:441-451. https://doi.org/10.1017/S1461145704004663
  22. Yen JY, Tu HP, Chen CS, Yen CF, Long CY, Ko CH. The effect of serotonin 1A receptor polymorphism on the cognitive function of premenstrual dysphoric disorder. Eur Arch Psychiatry Clin Neurosci 2014;264:729-739. https://doi.org/10.1007/s00406-013-0466-4
  23. Dhingra V, Magnay JL, O'Brien PM, Chapman G, Fryer AA, Ismail KM. Serotonin receptor 1A C(-1019)G polymorphism associated with premenstrual dysphoric disorder. Obstet Gynecol 2007;110:788-792. https://doi.org/10.1097/01.AOG.0000284448.73490.ac
  24. Donaldson ZR, le Francois B, Santos TL, Almli LM, Boldrini M, Champagne FA, et al. The functional serotonin 1a receptor promoter polymorphism, rs6295, is associated with psychiatric illness and differences in transcription. Transl Psychiatry 2016;6:e746. https://doi.org/10.1038/tp.2015.226
  25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, version IV, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association;2000. p.75.
  26. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-487.
  27. Abnormal Involuntary Movement Scale (AIMS). Psychopharmacol Bull 1988;24:781-783.
  28. Park YM, Kang SG, Choi JE, Kim YK, Kim SH, Park JY, et al. No Evidence for an association between dopamine D2 receptor polymorphisms and tardive dyskinesia in Korean schizophrenia patients. Psychiatry Investig 2011;8:49-54. https://doi.org/10.4306/pi.2011.8.1.49
  29. Lee HJ, Kang SG, Choi JE, Park YM, Lim SW, Rhee MK, et al. No Evidence for Association between Tyrosine Hydroxylase Gene Val81Met Polymorphism and Susceptibility to Tardive Dyskinesia in Schizophrenia. Psychiatry Investig 2009;6:108-111. https://doi.org/10.4306/pi.2009.6.2.108
  30. Lee HJ, Kang SG, Choi JE, Paik JW, Kim YK, Kim SH, et al. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia. Neuropsychobiology 2007;55:47-51. https://doi.org/10.1159/000103576
  31. Lee HJ, Kang SG, Paik JW, Lee MS, Cho BH, Park YM, et al. No evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia. Hum Psychopharmacol 2007;22:501-504. https://doi.org/10.1002/hup.875
  32. Kim IS, Yoon HK, Kang SG, Park YM, Kim YK, Kim SH, et al. No association between PAWR gene polymorphisms and tardive dyskinesia in schizophrenia patients. Psychiatry Investig 2012;9:191-194. https://doi.org/10.4306/pi.2012.9.2.191
  33. Kang SG, Choi JE, Park YM, Lee HJ, Han C, Kim YK, et al. Val158Met polymorphism in the catechol-O-methyltransferase (COMT) gene is not associated with tardive dyskinesia in schizophrenia. Neuropsychobiology 2008;57:22-25. https://doi.org/10.1159/000123118
  34. Kang SG, Choi JE, An H, Park YM, Lee HJ, Han C, et al. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1844-1847. https://doi.org/10.1016/j.pnpbp.2008.08.013
  35. Kang SG, Choi JE, An H, Lim SW, Lee HJ, Han C, et al. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1545-1548. https://doi.org/10.1016/j.pnpbp.2008.05.016
  36. Kang SG, Lee HJ, Choi JE, An H, Rhee M, Kim L. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia. Hum Psychopharmacol 2009;24:55-60. https://doi.org/10.1002/hup.988
  37. Cho CH, Lee HJ. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog Neuropsychopharmacol Biol Psychiatry 2013;46:207-213. https://doi.org/10.1016/j.pnpbp.2012.10.018
  38. Son WY, Lee HJ, Yoon HK, Kang SG, Park YM, Yang HJ, et al. Gaba transporter SLC6A11 gene polymorphism associated with tardive dyskinesia. Nord J Psychiatry 2014;68:123-128. https://doi.org/10.3109/08039488.2013.780260
  39. Johnson SK, Wagner GC, Fischer H. Neurochemical and motor effects of high dose haloperidol treatment: exacerbation by tryptophan supplementation. Proc Soc Exp Biol Med 1992;200:571-575. https://doi.org/10.3181/00379727-200-43472
  40. Haleem DJ, Batool F, Khan NH, Kamil N, Ali O, Saify ZS, et al. Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats. Med Sci Monit 2002;8:BR354-361.
  41. Melamed E, Zoldan J, Friedberg G, Ziv I, Weizmann A. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Adv Neurol 1996;69:545-550.
  42. Meltzer HY, Nash JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991;43:587-604.
  43. Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001;6:225-229. https://doi.org/10.1038/sj/mp/4000842
  44. Marazziti D, Rossi A, Palego L, Giannaccini G, Naccarato A, Lucacchini A, et al. [3H]ketanserin binding in human brain postmortem. Neurochem Res 1997;22:753-757. https://doi.org/10.1023/A:1027366413289
  45. Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG. The role of 5-HT2A receptors in antipsychotic activity. Life Sci 1995;56:2209-2222. https://doi.org/10.1016/0024-3205(95)00210-W
  46. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2012;38:167-177. https://doi.org/10.1093/schbul/sbq042
  47. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28:203-209. https://doi.org/10.1097/JCP.0b013e318166c4d5
  48. Mombereau C, Arnt J, Mork A. Involvement of presynaptic 5-HT1A receptors in the low propensity of brexpiprazole to induce extrapyramidal side effects in rats. Pharmacol Biochem Behav 2017;153:141-146. https://doi.org/10.1016/j.pbb.2016.12.015
  49. Prinssen EP, Colpaert FC, Koek W. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 2002;453:217-221. https://doi.org/10.1016/S0014-2999(02)02430-5
  50. Samad N, Khan A, Perveen T, Haider S, Abdul Haleem M, Haleem DJ. Increase in the effectiveness of somatodendritic 5-HT-1A receptors in a rat model of tardive dyskinesia. Acta Neurobiol Exp (Wars) 2007;67:389-397.
  51. Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev 1992;72:165-229. https://doi.org/10.1152/physrev.1992.72.1.165
  52. Kelland MD, Freeman AS, Chiodo LA. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 1990;253:803-811.
  53. Haleem DJ, Shireen E, Haleem MA. Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1323-1329. https://doi.org/10.1016/j.pnpbp.2004.08.003